

LETTER TO THE EDITOR

Open Access

# Gleaning after the European Headache Federation consensus statement on refractory chronic migraine

Paolo Martelletti<sup>1,2\*</sup>, Christian Lampl<sup>3</sup>, Michael-Bjorn Russell<sup>4,5</sup>, Dimos-Dimitrios Mitsikostas<sup>6</sup> and on behalf of the ad hoc European Headache Federation Expert Group

## Correspondence/Findings

We appreciated the Comment Letter from the Austrian colleagues referring to the recently published Consensus Statement on clinical definition of refractory Chronic Migraine (rCM), authored by the European Headache Federation (EHF) Expert Group [1,2].

In this Comment Letter [3] the authors present *Chronische Migräne: Therapie, Therapieresistenz und Neuromodulation – Ein Konsensus-Statement*, a consensus statement on CM with and without medication overuse, therapeutic options, with particular focus on patients selection for Occipital Nerve Stimulation (ONS). This article was published in a non-indexed national journal, supported by the device manufacturer [4].

We would like to underline the structural difference existing between the EHF paper and the Austrian one: the first one is finalized to the clinical definition of rCM and the proposal of criteria to be evaluated for a future inclusion of rCM as 3-digit diagnosis of CM in the next ICHD-3 (1.3.1 Refractory Chronic Migraine). The latter mostly targets to patients selection for ONS: "Diagnostic criteria for rCM and guidelines for managing targets patients with rCM and selecting candidates for invasive neuromodulation are crucial issues [4]". In contrast, the EHF Consensus clearly states "The European Headache Federation felt to develop new consensus criteria that define rCM, particularly for the purposes of controlled clinical trials that involve experimental medication and neuromodulation independently from the non-invasive therapies or the implantable devices [1,5]".

In particular four points should be addressed:

1. The Notified Body has just removed the CE mark from the only ONS device previously approved for

rCM patients [6]. Therefore, any speculation on the definition of rCM criteria useful for ONS selection [4,7] falls exclusively on future randomized controlled trials (RCTs).

2. The semantic debate on EHF criteria "requiring at least 3 different drugs from the following classes" [4] is a misinterpretation of our words: "at least 3 drugs from the following classes" (clearly shown on Table two in our publication) contains 5 classes, 4 of which do not reach 3 items [1]. This fact clearly shows the inconsistency of this criticism. Furthermore, the observation on the minimum dose of prophylactic drugs used is not at all useful in a contest of a definition of refractoriness.
3. The EHF proposed criteria for rCM are defined "inconsistent with respect to MO, since criterion A requires no MO, but recommendations for detoxification are given in the notes". We think that the wide acceptance of any kind of detoxification procedure guarantees ICHD-3 beta CM diagnosis an uncomplicated purity from acute drugs abuse that might be a confusing factor in the given criteria.
4. The criticism about "laboratory and CSF analyses within the normal range, including CSF pressure", as reported in the notes at Table two of the EHF Statement, should be seen as a wide evaluation opportunity of many forms of secondary headaches without decontextualize the phrase deleting the term "laboratory".

We thank the authors of the letter for taking the time to comment our paper, yet this falls partially into our purposes to initiate a European and worldwide discussion on the refractoriness of primary headache disorders, coagulating the various emerging attempts [8].

\* Correspondence: Paolo.Martelletti@uniroma1.it

<sup>1</sup>Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

<sup>2</sup>Regional Referral Headache Centre, Sant'Andrea Hospital, Rome, Italy

Full list of author information is available at the end of the article

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

All authors have equally contributed to the manuscript.

### Acknowledgements

All the authors did not receive any kind of direct or indirect compensation in preparing this manuscript.

### Author details

<sup>1</sup>Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. <sup>2</sup>Regional Referral Headache Centre, Sant'Andrea Hospital, Rome, Italy. <sup>3</sup>Headache Center Seilerstaette, Department of Neurogeriatric medicine and Remobilisation, Hospital Barmherzige Schwestern Linz, Lørenskog, Austria. <sup>4</sup>Head and Neck Research Group, Research Center, Akershus University Hospital, Lørenskog, Norway. <sup>5</sup>Institute of Clinical Medicine, Campus Akershus University Hospital, University of Oslo, Nordbyhagen, Norway. <sup>6</sup>Department of Neurology, Naval Hospital, Athens, Greece.

Received: 10 November 2014 Accepted: 10 November 2014

Published: 13 November 2014

### References

1. Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, Russell MB, Mitsikostas DD, Jensen RHJ (2014) Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. *J Headache Pain* 15:47
2. Lampl C, Jensen R, Martelletti P, Mitsikostas DD (2014) Refractory headache: one term does not cover all—a statement of the European headache federation. *J Headache Pain* 15:50
3. Wöber C, Wessely P (2014) Comment on: Martelletti et al. refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. *J Headache Pain* 15:77
4. Lüthringhausen G, Alesch F, Brössner G, Sator-Katzenschlager S, Vesper J, Wessely P, Wöber C (2014) Chronische Migräne: Therapie, Therapieresistenz und Neuromodulation - Ein Konsensus-Statement. *J Neurol Neurochir Psychiatr* 15:163–168
5. Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, Franzini A, Fontaine D, Heiland M, Jürgens TP, Leone M, Magis D, Paemeleire K, Palmisani S, Paulus W, May A (2013) Neuromodulation of chronic headaches: position statement from the European headache federation. *J Headache Pain* 14:86
6. Ministero della Salute (2014). [http://www.salute.gov.it/portale/news/p3\\_2\\_1\\_3\\_1\\_1.jsp?lingua=Italiano&menu=notizie&p=avvisi&tipo=dispo&id=3788](http://www.salute.gov.it/portale/news/p3_2_1_3_1_1.jsp?lingua=Italiano&menu=notizie&p=avvisi&tipo=dispo&id=3788) (last day accessed: November 5th, 2014)
7. Palmisani S, Al-Kaisi A, Arcioni R, Smith T, Negro A, Lambru G, Bandikatla V, Carson E, Martelletti P (2013) A six year retrospective review of occipital nerve stimulation practice—controversies and challenges of an emerging technique for treating refractory headache syndromes. *J Headache Pain* 14:67
8. Dong Z, Yin Z, He M, Chen X, Lv X, Yu S (2014) Validation of a guideline-based decision support system for the diagnosis of primary headache disorders based on ICHD-3 beta. *J Headache Pain* 15:40

doi:10.1186/1129-2377-15-75

**Cite this article as:** Martelletti et al.: Gleaning after the European headache federation consensus statement on refractory chronic migraine. *The Journal of Headache and Pain* 2014 **15**:75.

**Submit your manuscript to a SpringerOpen® journal and benefit from:**

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)